Floatz logo

Durvalumab

Gynaecological Cancers

Institute of Cancer Research, United Kingdommonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Gynaecological Cancers cohort.

Asset / SponsorPhaseRating
Inno-206
AstraZeneca
Phase 2BB
Carboplatin
AbbVie
Phase 2/3BB
Indocyanine Green
Istanbul University
Phase 4BB
NORMAL HUMAN SERUM ALBUMIN
Joachim Zdolsek
Phase 4B
Ringer's acetate
Joachim Zdolsek
Phase 4B

View all 50 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →